Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71.4M
-
Number of holders
-
95
-
Total 13F shares, excl. options
-
52.5M
-
Shares change
-
-2.05M
-
Total reported value, excl. options
-
$117M
-
Value change
-
-$3.49M
-
Put/Call ratio
-
0.56
-
Number of buys
-
47
-
Number of sells
-
-62
-
Price
-
$2.22
Significant Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q3 2025
129 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2025.
C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) has 95 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52.5M shares
of 71.4M outstanding shares and own 73.62% of the company stock.
Largest 10 shareholders include Lynx1 Capital Management LP (7.1M shares), Soleus Capital Management, L.P. (7.05M shares), ORBIMED ADVISORS LLC (5.24M shares), MORGAN STANLEY (4.97M shares), WASATCH ADVISORS LP (4.85M shares), VANGUARD GROUP INC (3.19M shares), BANK OF AMERICA CORP /DE/ (2.05M shares), MILLENNIUM MANAGEMENT LLC (1.93M shares), SILVERARC CAPITAL MANAGEMENT, LLC (1.9M shares), and BlackRock, Inc. (1.6M shares).
This table shows the top 95 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.